646 related articles for article (PubMed ID: 12084468)
1. New developments in anti-HIV chemotherapy.
De Clercq E
Biochim Biophys Acta; 2002 Jul; 1587(2-3):258-75. PubMed ID: 12084468
[TBL] [Abstract][Full Text] [Related]
2. New anti-HIV agents and targets.
De Clercq E
Med Res Rev; 2002 Nov; 22(6):531-65. PubMed ID: 12369088
[TBL] [Abstract][Full Text] [Related]
3. New developments in anti-HIV chemotherapy.
De Clercq E
Curr Med Chem; 2001 Nov; 8(13):1543-72. PubMed ID: 11562282
[TBL] [Abstract][Full Text] [Related]
4. Novel compounds in preclinical/early clinical development for the treatment of HIV infections.
De Clercq E
Rev Med Virol; 2000; 10(4):255-77. PubMed ID: 10891872
[TBL] [Abstract][Full Text] [Related]
5. New developments in anti-HIV chemotherapy.
De Clercq E
Farmaco; 2001; 56(1-2):3-12. PubMed ID: 11347962
[TBL] [Abstract][Full Text] [Related]
6. Emerging anti-HIV drugs.
De Clercq E
Expert Opin Emerg Drugs; 2005 May; 10(2):241-73. PubMed ID: 15934866
[TBL] [Abstract][Full Text] [Related]
7. HIV-chemotherapy and -prophylaxis: new drugs, leads and approaches.
De Clercq E
Int J Biochem Cell Biol; 2004 Sep; 36(9):1800-22. PubMed ID: 15183346
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.
Witvrouw M; Pannecouque C; Switzer WM; Folks TM; De Clercq E; Heneine W
Antivir Ther; 2004 Feb; 9(1):57-65. PubMed ID: 15040537
[TBL] [Abstract][Full Text] [Related]
9. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.
De Clercq E
Int J Antimicrob Agents; 2009 Apr; 33(4):307-20. PubMed ID: 19108994
[TBL] [Abstract][Full Text] [Related]
10. The history of antiretrovirals: key discoveries over the past 25 years.
De Clercq E
Rev Med Virol; 2009 Sep; 19(5):287-99. PubMed ID: 19714702
[TBL] [Abstract][Full Text] [Related]
11. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
[TBL] [Abstract][Full Text] [Related]
12. Antiviral drugs in current clinical use.
De Clercq E
J Clin Virol; 2004 Jun; 30(2):115-33. PubMed ID: 15125867
[TBL] [Abstract][Full Text] [Related]
13. Anti-HIV drugs.
De Clercq E
Verh K Acad Geneeskd Belg; 2007; 69(2):81-104. PubMed ID: 17550060
[TBL] [Abstract][Full Text] [Related]
14. New perspectives for the treatment of HIV infections.
De Clercq E
Verh K Acad Geneeskd Belg; 1998; 60(1):13-41; discussion 41-5. PubMed ID: 9646721
[TBL] [Abstract][Full Text] [Related]
15. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.
De Clercq E
Antiviral Res; 1998 Jun; 38(3):153-79. PubMed ID: 9754886
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationship studies on clinically relevant HIV-1 NNRTIs.
Rawal RK; Murugesan V; Katti SB
Curr Med Chem; 2012; 19(31):5364-80. PubMed ID: 22998569
[TBL] [Abstract][Full Text] [Related]
17. New antiretroviral drugs.
Gulick RM
Clin Microbiol Infect; 2003 Mar; 9(3):186-93. PubMed ID: 12667250
[TBL] [Abstract][Full Text] [Related]
18. Advances in rationally designed dual inhibitors of HIV-1 reverse transcriptase and integrase.
Gu SX; Xue P; Ju XL; Zhu YY
Bioorg Med Chem; 2016 Nov; 24(21):5007-5016. PubMed ID: 27658796
[TBL] [Abstract][Full Text] [Related]
19. The development of anti-HIV-1 drugs.
Lu XF; Chen ZW
Yao Xue Xue Bao; 2010 Feb; 45(2):165-76. PubMed ID: 21348415
[TBL] [Abstract][Full Text] [Related]
20. CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro.
Vermeire K; Princen K; Hatse S; De Clercq E; Dey K; Bell TW; Schols D
AIDS; 2004 Nov; 18(16):2115-25. PubMed ID: 15577644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
